ABT · News · 20261113N

Revenue Performance and Mix

ABBOTT LABORATORIES · 2026-11-13 · Importance 35 · Surprise 22 · No source text

Abbott reported third-quarter 2026 sales of $13.01 billion, up 14.5% year over year and 0.3% above the Zacks Consensus Estimate. Established Pharmaceuticals grew broadly across geographies and therapeutic areas; Medical Devices recorded double-digit growth in Electrophysiology and Rhythm Management. Diagnostics benefited from Core Laboratory testing demand and Cancer Diagnostics momentum, while adjusted EPS rose 9.2% to $1.42 and fell 0.7% short of consensus.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
revenuepositiverealized+12.7%Abbott's Q3 2026 sales increased 14.5% year over year to $13.01 billion and exceeded the Zacks Consensus Estimate by 0.3%.